Answers are grounded in this paper and cite their sources.
INTRODUCTION: Clinical characteristics and outcomes of patients with massive gamma-hydroxybutyrate exposure are poorly characterised. We describe clinical features, outcomes and influence of common co-detections in patients with analytically massive gamma-hydroxybutyrate exposure. METHODS: Retrospective multicentre cohort study using the Emerging Drugs Network of Australia-Victoria registry. Patients presenting to 18 Victorian emergency departments between November 2021 and March 2026 with whole blood gamma-hydroxybutyrate concentrations ≥300 mg/L (2.9 mmol/L). Clinical features, complications, interventions, and outcomes were described. Multivariable logistic regression examined associations between whole blood gamma-hydroxybutyrate concentration, opioid, benzodiazepine, and methamphetamine co-detection and five clinical domains: severe CNS depression (Glasgow Coma Scale of three), bradypnoea, hypoxaemia, hypotension, and hypothermia. RESULTS: A total of 154 patients were included. Median age was 33 years (IQR 28-40); median whole blood gamma-hydroxybutyrate concentration 380 mg/L (3.7 mmol/L), IQR 340-470 mg/L (3.3-4.5 mmol/L). Severe CNS depression was common (116/154 (75%) had a first Glasgow Coma Scale of three), as were intubation 101/154 (66%), intensive care admission (103/154, 67%), hypotension (39/154, 25%), vasopressor use (31/154, 20%), and hypothermia (56/154, 36%). Polysubstance exposure occurred in 150/154 (97%). Opioid co-detection (31/154, 20%) was independently associated with hypotension (adjusted odds ratio [aOR] 4.51, 95% confidence interval [CI] 1.83-11.14) and hypoxaemia (aOR 3.64, 95% CI 1.14-11.67). Higher whole blood gamma-hydroxybutyrate concentration was independently associated with hypotension but not CNS depression, bradypnoea, hypoxaemia, or hypothermia. One patient died (0.6%) and 42/154 (27%) were discharged directly from the emergency department. DISCUSSION: Massive gamma-hydroxybutyrate exposure produced a remarkably consistent severe but largely reversible toxidrome. Within the massive exposure range studied, increasing gamma-hydroxybutyrate concentration contributed principally to haemodynamic compromise, whereas common co-detections had little influence apart from opioid-associated hypotension and hypoxaemia. CONCLUSION: Massive gamma-hydroxybutyrate exposure was associated with profound but largely reversible toxicity and excellent in-hospital survival with supportive care. These findings support aggressive early supportive management and identify haemodynamic compromise as remaining concentration-dependent in the massive exposure range.
No takes yet. Share an insight, caveat, or question.
Greene et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: